E
Emma Forrest
Publications - 4
Citations - 436
Emma Forrest is an academic researcher. The author has contributed to research in topics: Safinamide & Dyskinesia. The author has an hindex of 3, co-authored 4 publications receiving 340 citations.
Papers
More filters
Journal ArticleDOI
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Rupam Borgohain,József Attila Szász,Paolo Stanzione,Chandrashekhar Meshram,Mohit Bhatt,D. Chirilineau,Fabrizio Stocchi,V. Lucini,R. Giuliani,Emma Forrest,P. Rice,R. Anand,M. Illiyas Sahadulla,U. Kardan,B. S. Keshava,A. Kishore,S. S. Kothari,J. M. Krishna Murthy,S. Kumar,P. Kumar Pal,N. Mehta,S. Prabhakar,S. Kr Prabhakar,S. Pradhan,A. K. Roy,C. Sankhla,P. K. Sethi,Amy Shah,N. Shankar,R. Shukla,A. Sowani,R. Srinivasa,M. Varma,D. Vasudevan,P. Vavilikolanu Sreenivas,C. U. Velmurugendran,K. Vijayan,Ovidiu Bajenaru,A. Bulboaca,A. Campeanu,D. Chirileanu,D. Muresanu,C. Panea,C. D. Popescu,Mihaela Simu,M. Ticmeanu,Tania P. Avarello,Ubaldo Bonuccelli,Roberto Eleopra,Marco Onofrj,Rocco Quatrale +50 more
TL;DR: The addition of safinamide 50 mg/day or 100mg/day to l‐dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating thatsafinamide improves motor symptoms and parkinsonistan without worsening dyskineia.
Journal ArticleDOI
Two-Year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
Rupam Borgohain,József Attila Szász,Paolo Stanzione,Chandrashekhar Meshram,Mohit Bhatt,Dana Chirilineau,Fabrizio Stocchi,V. Lucini,R. Giuliani,Emma Forrest,Patricia Rice,R. Anand +11 more
TL;DR: This 2‐year, controlled study of add‐on safinamide in mid‐to‐late Parkinson's disease with motor fluctuations showed improvement in dyskinesia in patients at least moderately dyskinetic at baseline, and demonstrated significant clinical benefits in ON‐time (without troublesome dysKinesia), OFF‐time, activities of daily living, motor symptoms, quality of life, and symptoms of depression.
Journal ArticleDOI
T48. antipsychotic efficacy of evenamide (nw-3509) is due to modulation of glutamatergic dysregulation.
TL;DR: The results indicate it is essential to modulate mechanisms other than dopaminergic (DA)/serotoninergic (5-HT) systems to improve symptoms of schizophrenia (SCZ) and that evenamide’s Glu antagonism is of value in patients worsening on current antipsychotics.
Journal ArticleDOI